BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bagaglio S, Uberti-Foppa C, Morsica G. Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Drugs 2017;77:1043-55. [PMID: 28497432 DOI: 10.1007/s40265-017-0753-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Martínez I, Ryan P, Valencia J, Resino S. The Challenging Road to Hepatitis C Virus Eradication. J Clin Med 2021;10:611. [PMID: 33562818 DOI: 10.3390/jcm10040611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Wong A, Tsien C, Mansour S, Cooper C. Remaining clinical issues in hepatitis C treatment. CanLivJ 2018;1:66-77. [DOI: 10.3138/canlivj.1.2.006] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Eyer L, Nougairède A, Uhlířová M, Driouich JS, Zouharová D, Valdés JJ, Haviernik J, Gould EA, De Clercq E, de Lamballerie X, Ruzek D. An E460D Substitution in the NS5 Protein of Tick-Borne Encephalitis Virus Confers Resistance to the Inhibitor Galidesivir (BCX4430) and Also Attenuates the Virus for Mice. J Virol 2019;93:e00367-19. [PMID: 31142664 DOI: 10.1128/JVI.00367-19] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
4 Zuccaro V, Lombardi A, Asperges E, Sacchi P, Bruno R. PK/PD and antiviral activity of anti-HCV therapy: is there still a role in the choice of treatment? Expert Opin Drug Metab Toxicol 2020;16:97-101. [PMID: 32003256 DOI: 10.1080/17425255.2020.1721459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Zeng H, Li L, Hou Z, Zhang Y, Tang Z, Liu S. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. Int J Med Sci. 2020;17:892-902. [PMID: 32308542 DOI: 10.7150/ijms.43079] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
6 Chandra P, Enespa, Singh R, Arora PK. Microbial lipases and their industrial applications: a comprehensive review. Microb Cell Fact 2020;19:169. [PMID: 32847584 DOI: 10.1186/s12934-020-01428-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 17] [Article Influence: 23.0] [Reference Citation Analysis]
7 Anticoli S, Amatore D, Matarrese P, De Angelis M, Palamara AT, Nencioni L, Ruggieri A. Counteraction of HCV-Induced Oxidative Stress Concurs to Establish Chronic Infection in Liver Cell Cultures. Oxid Med Cell Longev 2019;2019:6452390. [PMID: 30906503 DOI: 10.1155/2019/6452390] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
8 Li X, Li J, Feng Y, Cai H, Li YP, Peng T. Long-chain fatty acyl-coenzyme A suppresses hepatitis C virus infection by targeting virion-bound lipoproteins. Antiviral Res. 2020;177:104734. [PMID: 32057770 DOI: 10.1016/j.antiviral.2020.104734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Duncan JD, Urbanowicz RA, Tarr AW, Ball JK. Hepatitis C Virus Vaccine: Challenges and Prospects. Vaccines (Basel) 2020;8:E90. [PMID: 32079254 DOI: 10.3390/vaccines8010090] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
10 Cuypers L, Thijssen M, Shakibzadeh A, Sabahi F, Ravanshad M, Pourkarim MR. Next-generation sequencing for the clinical management of hepatitis C virus infections: does one test fits all purposes? Crit Rev Clin Lab Sci 2019;56:420-34. [PMID: 31317801 DOI: 10.1080/10408363.2019.1637394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Marascio N, Pavia G, Romeo I, Talarico C, Di Salvo S, Reale M, Marano V, Barreca GS, Fabiani F, Perrotti N, De Siena M, Giancotti F, Gravina T, Alcaro S, Artese A, Torti C, Liberto MC, Focà A. Real-life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling. J Med Virol 2018;90:1257-63. [PMID: 29575060 DOI: 10.1002/jmv.25073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
12 Mammari N, Krier Y, Albert Q, Devocelle M, Varbanov M, On Behalf Of The Oemonom. Plant-Derived Antimicrobial Peptides as Potential Antiviral Agents in Systemic Viral Infections. Pharmaceuticals (Basel) 2021;14:774. [PMID: 34451871 DOI: 10.3390/ph14080774] [Reference Citation Analysis]
13 Dinu S, Țârdei G, Ceaușu E, Florescu SA, Micu L, Ecobici AM, Mihăilă M, Oprișan G. Detection of anti-protease inhibitors resistance mutations in HCV strains infecting treatment-naïve chronic patients from Romania. Revista Romana de Medicina de Laborator 2018;26:443-9. [DOI: 10.2478/rrlm-2018-0029] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Marascio N, Quirino A, Barreca GS, Galati L, Costa C, Pisani V, Mazzitelli M, Matera G, Liberto MC, Focà A, Torti C. Discussion on critical points for a tailored therapy to cure hepatitis C virus infection. Clin Mol Hepatol 2019;25:30-6. [PMID: 30669818 DOI: 10.3350/cmh.2018.0061] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
15 Serranti D, Indolfi G, Caudai C, Bartolini E, Trapani S, Zazzi M, Resti M. Hepatitis C Genotype 4 Virus Nonstructural 3 and Nonstructural 5A Resistance-associated Substitutions in a 16-year-old Adolescent Failing Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin. Pediatr Infect Dis J 2019;38:e72-4. [PMID: 30882744 DOI: 10.1097/INF.0000000000002137] [Reference Citation Analysis]
16 Arba M, Wahyudi ST, Zubair MS, Brunt D, Singh M, Wu C. Binding of GS-461203 and Its Halogen Derivatives to HCV Genotype 2a RNA Polymerase Drug Resistance Mutants. Sci Pharm 2022;90:26. [DOI: 10.3390/scipharm90020026] [Reference Citation Analysis]
17 Asante-Appiah E, Liu R, Curry S, McMonagle P, Agrawal S, Carr D, Rokosz L, Lahser F, Bystol K, Chase R, Black S, Ferrari E, Ingravallo P, Tong L, Yu W, Kozlowski J. In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A. Antimicrob Agents Chemother 2018;62:e01280-18. [PMID: 30150466 DOI: 10.1128/AAC.01280-18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Li J, Abosmaha E, Coffin CS, Labonté P, Bukong TN. Reticulon-3 modulates the incorporation of replication competent hepatitis C virus molecules for release inside infectious exosomes. PLoS One 2020;15:e0239153. [PMID: 32941510 DOI: 10.1371/journal.pone.0239153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Esposito I, Marciano S, Haddad L, Galdame O, Franco A, Gadano A, Flichman D, Trinks J. Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection. Viruses 2018;11:E3. [PMID: 30577623 DOI: 10.3390/v11010003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
20 Song Y, Yang X, Shen Y, Wang Y, Xia X, Zhang AM. STAT3 signaling pathway plays importantly genetic and functional roles in HCV infection. Mol Genet Genomic Med 2019;7:e821. [PMID: 31219249 DOI: 10.1002/mgg3.821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
21 Abdel-Hameed EA, Rouster SD, Boyce CL, Zhang X, Biesiada J, Medvedovic M, Sherman KE. Ultra-Deep Genomic Sequencing of HCV NS5A Resistance-Associated Substitutions in HCV/HIV Coinfected Patients. Dig Dis Sci 2018;63:645-52. [PMID: 29330726 DOI: 10.1007/s10620-017-4895-1] [Reference Citation Analysis]
22 Lee S, Mailar K, Kim MI, Park M, Kim J, Min DH, Heo TH, Bae SK, Choi W, Lee C. Plant-Derived Purification, Chemical Synthesis, and In Vitro/In Vivo Evaluation of a Resveratrol Dimer, Viniferin, as an HCV Replication Inhibitor. Viruses 2019;11:E890. [PMID: 31547617 DOI: 10.3390/v11100890] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
23 Abdel-aal FA, Rageh AH, Said MI, Saleh GA. ε-MnO2-modified graphite electrode as a novel electrochemical sensor for the ultrasensitive detection of the newly FDA approved Hepatitis C antiviral drug ledipasvir. Analytica Chimica Acta 2018;1038:29-40. [DOI: 10.1016/j.aca.2018.07.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
24 Ramesh D, Vijayakumar BG, Kannan T. Therapeutic potential of uracil and its derivatives in countering pathogenic and physiological disorders. Eur J Med Chem 2020;207:112801. [PMID: 32927231 DOI: 10.1016/j.ejmech.2020.112801] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
25 Hamed M, El-Hasab M, Mansour FR. Direct acting anti-hepatitis C combinations as potential COVID-19 protease inhibitors. Virusdisease 2021;:1-7. [PMID: 33948452 DOI: 10.1007/s13337-021-00691-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]